Please assess the completion status of the following clinical trial:

Trial Title: Blind Child Melatonin Treatment Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Children and adults 5 to 20 years old~* Blindness for at least one year, verified by an ophthalmologic exam~* Ability to comply with the requirements of the experimental protocol~* And no clinically significant abnormalities (other than blindness) on a general physical examination.~* Subjects must be competent to sign informed consent if age 18 or older. Parents and subjects will be interviewed together and, when appropriate (for example, subject is age 18 or older), separately as well.~Exclusion Criteria:~* Abnormal heart, liver or kidney function; intractable seizure disorders~* Significant laboratory abnormalities on CBC, Comprehensive Metabolic set, or UA (dip stick method)~* Pregnancy; sexual activity in post-pubertal females not using a recognized and valid contraceptive method~* A current Axis I psychiatric or substance abuse disorder according to the DSM-IV Manual ; OR~* External demands that limit the ability to maintain a regular schedule, e.g. night shift work.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Subjects will be given up to 0.5 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
- 2 (Type: EXPERIMENTAL): Subjects will be given up to 10 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
- 3 (Type: EXPERIMENTAL): Subjects will be given up to 20 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.

Based on this trial design, predict the completion outcome and termination type (if applicable).